Association between overt hepatic encephalopathy and liver pathology after transjugular intrahepatic portosystemic shunt creation in cirrhotic patients

Sci Rep. 2025 Jan 9;15(1):1548. doi: 10.1038/s41598-025-86176-8.

Abstract

To investigate the association between overt hepatic encephalopathy (OHE) and liver pathology after transjugular intrahepatic portosystemic shunt (TIPS) creation in cirrhotic patients. From July 2015 to April 2024, 73 patients from 4 hospitals in China who received TIPS creation and liver biopsy were retrospectively enrolled in this study. Based on whether OHE occurred within 3 months after TIPS creation, the patients were categorized into OHE (n = 29) and non-OHE (n = 44) groups. The liver pathology was assessed by hematoxylin-eosin (H&E), Sirius red staining, immunohistochemistry, and immunofluorescence. Liver pathology by H&E staining showed typical features of liver cirrhosis (including disordered structure and pseudolobule formation) in all the patients. No marked difference was observed in extracellular matrix (ECM) deposition between the OHE and non-OHE groups. However, the patients in the OHE group had a higher level of liver and systemic inflammation than in the non-OHE group. And there was a strong correction between intrahepatic macrophage infiltration and serum inflammatory indicators. Additionally, the OHE group had more liver neovascularization, which was consistent with liver inflammation. The emergence of OHE after TIPS creation is closely associated with liver pathology, especially in liver inflammation and angiogenesis, but not in ECM deposition.

Keywords: Angiogenesis; Inflammation; Liver cirrhosis; Overt hepatic encephalopathy; Transjugular intrahepatic portosystemic shunt.

MeSH terms

  • Adult
  • Aged
  • Female
  • Hepatic Encephalopathy* / etiology
  • Hepatic Encephalopathy* / pathology
  • Humans
  • Liver Cirrhosis* / etiology
  • Liver Cirrhosis* / pathology
  • Liver Cirrhosis* / surgery
  • Liver* / metabolism
  • Liver* / pathology
  • Male
  • Middle Aged
  • Portasystemic Shunt, Transjugular Intrahepatic* / adverse effects
  • Retrospective Studies